

1 Post-acute sequelae of COVID-19 and adverse psychiatric outcomes: an etiology and risk 2 systematic review protocol

3 **Andem Effiong¹**

4 1. Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland
5 and Labrador, Canada

6 Correspondence to: Andem Effiong; andem.effiong@me.com

7 **ABSTRACT**

8 **Introduction** The post-acute sequelae of COVID-19 (PASC) is a syndrome characterized by
9 persistent COVID-19 symptoms or the onset of new symptoms following recovery from the
10 initial or acute phase of the illness. Such symptoms often occur four or more weeks after being
11 diagnosed with COVID-19. Although a lot of work has gone into understanding the long-term
12 mental health effects of PASC, many questions related to the etiology and risk of this condition
13 remain. Thus, this protocol is for a systematic review assessing the association between PASC
14 and adverse psychiatric outcomes and whether people with PASC are at greater risk of
15 developing an adverse psychiatric outcome than those without PASC.

16 **Methods and analysis** Various medical databases (e.g., PubMed and EMBASE) will be
17 searched for eligible articles using predefined search criteria. Gray literature will also be
18 explored. Epidemiological observational studies and secondary analyses of randomized
19 controlled trials that report a quantitative relationship between PASC and at least one adverse
20 psychiatric outcome will be included. The Population, Exposure of interest, Comparator, and
21 Outcome (PECO) framework will be used as a standardized framework for the inclusion criteria.
22 The Joanna Briggs Institute (JBI) critical appraisal tools will be used to assess methodological
23 quality and critically appraise the risk of bias in included studies. A random-effects meta-
24 analysis will be conducted if possible. A formal narrative synthesis will be performed if a meta-
25 analysis is impossible due to substantial heterogeneity across studies. The Grading of
26 Recommendations Assessment, Development and Evaluation (GRADE) approach will be used to
27 rate the cumulative certainty of the evidence for all outcomes.

28 **Ethics and Dissemination** Ethical approval is not required for this study. The study results will
29 be published in a peer-reviewed journal.

30 **Prospero registration number** [CRD42022308737](https://doi.org/10.1111/1744-4789.12345)

31

32

33

34 **Strengths and limitations of this study**

- 35 ■ This study documents and addresses etiology, risk factors, and long-term symptoms of
36 COVID-19 among people with post-acute sequelae of COVID-19 (PASC).

- 37 ▪ It focuses on a key priority area for new evidence syntheses on the clinical management
- 38 of COVID-19 and pandemic-related conditions.
- 39 ▪ It will include evidence on non-hospitalized and hospitalized patients with a history of
- 40 PASC.
- 41 ▪ Substantial heterogeneity across studies may limit the ability to perform a meta-analysis.
- 42 ▪ Findings will inform disease prevention, decision-making, healthcare policy, and clinical
- 43 research.

44

45

46 **BACKGROUND**

47 **Rationale**

48 Coronavirus disease 2019 (COVID-19) is a contagious illness caused by the severe acute
49 respiratory syndrome coronavirus 2 (SARS-CoV-2). Persistent and long-lasting (>4 weeks)
50 symptoms following infection with acute COVID-19 have given rise to a syndrome known as
51 post-acute sequelae of COVID-19 (PASC) or long COVID.^{1, 2, 3} Incidence and prevalence
52 estimates for people with COVID-19 presenting with or reporting persistent psychiatric
53 symptoms months following initial infection range from 0.8 - 49%^{1,2,3,4,5} Among 44 759 people
54 with no recorded history of psychiatric illness, the estimated overall probability of being
55 diagnosed with new-onset psychiatric illness in the 90 days following a confirmed diagnosis of
56 COVID-19 was 5.8% in a retrospective cohort study.⁶ Similarly, clinical anxiety and depression,
57 as well as other psychiatric sequelae, have been reported following diagnosis with COVID-19 in
58 other studies.^{6,7, 8} Although sex and age are considered to be sociodemographic risk factors for
59 PASC, there is no consensus on other baseline clinical features that act as independent predictors
60 of PASC.^{9, 10} The prevalence of PASC symptoms is higher in women compared with men.¹⁰
61 Among people aged 35-49 years, the prevalence of PASC is 26.8% compared with 26.1% and
62 18% among people aged 50-69 years and 70 years or older, respectively.¹⁰

63 Persistent symptoms occur weeks and months after infection irrespective of initial disease
64 severity (mild, moderate, severe, critical).^{11, 12} Mendez et al. reported in their cross-sectional
65 study that two months after discharge, neurocognitive impairment, psychiatric morbidity, and
66 poor quality of life were markedly prevalent among 179 COVID-19 survivors who had been
67 hospitalized.¹² Nevertheless, Vannorsdall and Oh posit that current research on the post-acute
68 phase following hospitalization has been conflicting due to the absence of a detailed,
69 standardized neuropsychological evaluation of COVID-19 patients after hospitalization.¹³ In
70 addition, they stated that literature on PASC and adverse mental health outcomes are mostly
71 limited to studies that cannot establish causal relationships or lack generalizability (e.g., case
72 reports, case series, and data obtained from cognitive screening instruments).¹³ Thus, more high-
73 quality studies are warranted.¹³

74 In a study where the short-term and long-term sequelae of COVID-19 were systematically
75 evaluated, PASC was categorized as short-term (1 month), intermediate-term (2-5 months), and

76 long-term (≥ 6 months) following COVID-19 diagnosis.¹⁴ Clinical manifestations of PASC were
77 classified into organ systems, i.e., cardiovascular, dermatologic, digestive, ear, nose, and throat;
78 mental health, neurologic, and respiratory; constitutional symptoms; and functional mobility.¹⁴
79 The mechanisms leading to the post-acute and chronic neuropsychiatric manifestations of
80 COVID-19 may be due to the direct effect of the viral infection and the indirect effect on mental
81 health due to social isolation, post-traumatic stress, and job loss. Specifically, correlations have
82 been observed between COVID-19 post-traumatic stress scores, general distress, and sleep
83 disruption.^{14, 15} Despite those correlations, Khubchandani et al. stated that the causal pathways
84 and etiology of adverse mental health outcomes in people who were infected with COVID-19 are
85 multidimensional and complex.¹⁶

86 To clarify whether COVID-19 is a risk factor for psychiatric disorders and vice-versa, an
87 electronic health record network cohort study of 69 million people consisting of 62 354 people
88 with a COVID-19 diagnosis compared the rates of psychiatric sequelae of health in the initial
89 four months of the pandemic (January – April 2020) and subsequently (after April 2020).¹⁷ The
90 study found that the rate of all diagnoses of psychiatric disorders and relapses was greater
91 following a COVID-19 infection compared with after control health events (e.g., influenza
92 infection, skin infection, other respiratory tract infections, and fracture).¹⁷ Similarly, a diagnosis
93 of psychiatric disorder in the 12 months preceding the COVID-19 pandemic was associated with
94 a 65% increased risk of COVID-19 (relative risk (RR) = 1.65, 95% confidence interval (CI):
95 1.59-1.71; $p < 0.0001$) compared with a matched cohort of people with specific physical risk
96 factors for COVID-19 minus a psychiatric diagnosis.¹⁷ Whereas these associations were partly
97 attributed to illness severity and pandemic-related contextual factors (e.g., social isolation,
98 overwhelmed healthcare systems, and stigma), they do not adequately account for observed
99 differences in psychiatric sequelae.¹⁷ Moreover, the inability to conclusively determine why
100 there were between twofold and threefold increases in the risk of neurologic and psychiatric
101 complications following a COVID-19 infection, in this and other studies, calls for further
102 examination of the association between COVID-19 and risk factors for psychiatric morbidity.
103 ^{17,18, 19}

104 With many long-term adverse mental health outcomes linked to COVID-19, effective
105 interventions which optimize recovery and minimize relapse are needed. Such interventions may
106 serve as appropriate tools to evaluate risk factors that may cause maladaptive psychiatric
107 responses.²⁰ Furthermore, they may aid with the management of anxiety, fear, frustration,
108 stigma, and paranoia by mitigating psychopathological symptoms and reducing contextual
109 stress.²⁰ Interventions that have been assessed in COVID-19 patients include virtual and
110 physical psychotherapeutic approaches, e.g., cognitive behavioral therapy (CBT), emotional
111 freedom techniques (EFT), and ultra-brief psychological interventions (UBPI); combined
112 psychiatric and psychological interventions; technology and media; complementary and
113 alternative therapies; self-care; spirituality and religion; and pharmacological.^{21, 22}

114 Evidence on the effectiveness of these interventions is mixed and not thoroughly synthesized,
115 with quality inadequately assessed in earlier studies and may vary depending on COVID-19
116 duration and severity. In a randomized controlled clinical trial of 51 people with COVID-19

117 consisting of an experimental group receiving progressive muscle relaxation (PMR) technology
118 for 30 minutes each day for five consecutive days and a control group receiving only usual care
119 and treatment, subjects in the experimental group reported lower depressive symptoms, lower
120 anxiety levels, and better sleep quality compared with those in the control group.²³ Another
121 randomized control trial of 30 hospitalized patients with COVID-19 assigned to an experimental
122 or control group reported an improvement in all outcome measures among intervention group
123 subjects compared to controls.²⁴ In that study, a short four-session crisis intervention package
124 tailored to cover COVID-19-specific guidance was delivered by clinical psychologists.²⁴ Topics
125 covered included tension reduction, relaxation, adjustment, responsibility skills enhancement,
126 and promoting resilience.²⁴ Outcomes measures in the study were derived from the Depression,
127 Anxiety, and Stress Scale (DASS21), Symptom Checklist 25 (SCL-25), and the abbreviated
128 version of the World Health Organization Quality of Life assessment (WHOQOL-BREF).²⁴
129 Lack of cultural specificity, methodological issues, small sample sizes, lack of follow-up,
130 unadjusted confounding factors, and brief time spans in both studies limit their
131 generalizability.^{23, 24}

132 During the COVID-19 pandemic, digital interventions to deliver health care have gained
133 widespread acceptance.²⁵ Remote care coordination and provision have been adopted to help
134 reduce the risk of disease transmission.²⁵ Mobile applications have also been used for contact
135 tracing and information dissemination.²⁵ Although an evidence synthesis of digital interventions
136 to attenuate the adverse effects of the COVID-19 pandemic on public mental health highlighted
137 their importance in mental disorder prevention and mental health promotion; it noted that
138 evidence on their cost-effectiveness, process quality, and long-term outcomes is sparse.²⁶
139 Furthermore, the negative impact and risks of the COVID-19 pandemic are sometimes more
140 significant in vulnerable and clinically extremely vulnerable populations (e.g., people over the
141 age of 70, pediatric patients with cystic fibrosis, or people with developmental disabilities) who
142 may be digitally disadvantaged.^{26, 27, 28}

143 Presently, it is unclear what duration of PASC, etiologies and risk factors are most associated
144 with the manifestation or persistence of adverse psychiatric outcomes (e.g., depression, anxiety,
145 substance use disorder, post-traumatic stress disorder, psychosis, dementia, self-harm, suicide)
146 compared with other health events. A prospective cohort study of patient-reported outcome
147 measures (PROM) three months after initial COVID-19 symptom onset noted impairment with
148 self-care and anxiety or depression as being present in 13% and 22% of its 78 subjects with at
149 least one Charlson comorbidity at baseline compared to subjects without any Charlson
150 comorbidities (4% and 9% respectively). Among subjects without any Charlson comorbidities,
151 70% reported an abnormal PROM, and 33% had at least one moderate issue in at least one
152 EuroQol- 5 Dimension (EQ-5D).²⁹ In addition, questions remain about the long-term (≥ 6
153 months) outcomes of COVID-19.³⁰

154 Although some studies indicate that most people who acquire COVID-19 are at risk of
155 psychiatric sequelae and their symptoms tend to improve over time, others suggest that
156 symptoms may worsen over time or point to a different disease trajectory.^{30, 31} Research and any

157 future recommendations about PASC and mental health should be guided by the best available
158 evidence.

159 Few epidemiological studies have investigated the short and long-term impact of COVID-19
160 and PASC on mental health. Thus, this study will examine the causes of adverse psychiatric
161 outcomes and risk factors in people with PASC. Furthermore, prior studies on this and related
162 topics report internal validity and generalizability (external validity) limitations due to evidence
163 derived solely from electronic health records, single network, or claims data. Because data on the
164 psychiatric sequelae of PASC are conflicting and sparse, it is imperative to systematically
165 summarize the evidence and combine the results of various scientific studies. This study aims to
166 generate a new hypothesis on causality and provide a more precise estimate of the risk factors
167 underlying PASC and adverse psychiatric outcomes.

168 An initial search of peer-reviewed and gray literature found no systematic reviews and meta-
169 analyses on the topic. This protocol is for a systematic review that assesses the literature on
170 PASC duration and risk factors that act as determinants (etiologies) of adverse psychiatric
171 outcomes.

172

173 **Objectives**

174 The primary objective of this systematic review is to determine whether people with PASC are
175 at greater risk of developing an adverse psychiatric outcome (depression, anxiety, substance use
176 disorder, post-traumatic stress disorder, psychosis, dementia, suicide) than those without PASC.

177 Secondary review questions include the following:

- 178 ▪ Does the association between PASC and an adverse psychiatric outcome vary with age,
179 sex, the severity of COVID-19 (mild, moderate, severe, critical), and duration of PASC
180 (short-term (1 month), intermediate-term (2-5 months), and long-term (\geq 6 months)
181 following COVID-19 diagnosis or hospital discharge)?
- 182 ▪ Is PASC an independent risk factor for an adverse psychiatric outcome?

183

184 **METHODS**

185 This protocol has been drafted following the Preferred Reporting Items for Systematic Reviews
186 and Meta-Analyses (PRISMA) guidance for protocols (PRISMA-P).³² The systematic review
187 will explicitly report any amendments and modifications made to this protocol.

188 **Eligibility criteria**

189 *Study design/characteristics:* The review will include observational studies, namely,
190 retrospective and prospective longitudinal cohort, case-control, cross-sectional, case series, and
191 case reports. Secondary analyses of randomized controlled trials will also be included. Effect
192 measures of risk factors, e.g., risk difference, relative risk, odds ratio, and hazard ratio central to
193 the primary outcome, will be included. Risk factors predispose people with PASC to an adverse

194 psychiatric outcome. Such risk factors are associated with an increased probability of people
195 with PASC having a negative mental health outcome. Information on the relationship between
196 risk factors and incidence of primary and secondary outcome measures will be included. Studies
197 that do not report a quantitative relationship between PASC and at least one adverse psychiatric
198 outcome will be excluded.

199 COVID-19 diagnosis must have been confirmed through clinical suspicion or with a positive
200 nucleic acid amplification test (NAAT), e.g., reverse transcriptase-polymerase chain reaction
201 (RT-PCR); antigen test; or serologic test (e.g., rapid serology test (RST) or enzyme-linked
202 immunosorbent assay (ELISA)).³³ Studies will be included if subjects were longitudinally
203 observed since the initial diagnosis of COVID-19, i.e., during the acute phase or since the time of
204 PASC onset (post-acute or chronic phase). A follow-up time of at least one month since the
205 COVID-19 diagnosis is required. Primary and secondary outcomes will encompass etiology, risk
206 factors, symptom and illness severity, duration of PASC, and adverse events.

207 *Participants:* Studies with adults as subjects (18 years or older) will be included. Pediatric and
208 animal studies will not be included. There will be no sex, ethnicity, or race limitations. The
209 search dates will range from December 2019 (date of first confirmed case of COVID-19) until
210 March 2022 (the anticipated completion date of the review). COVID-19 filters will be used – if
211 necessary – to limit search results to COVID-19 and PASC related articles.

212 *Exposure:*

213 Primary measure

- 214 ▪ Post-acute sequelae of COVID-19 (PASC), for this review defined as a continuing
215 symptomatic illness or the emergence of new symptomatic illness in people with a
216 confirmed history of COVID-19 after recovery from the acute phase of illness. PASC
217 will be categorized as short-term (1 month), intermediate-term (2-5 months), and long-
218 term (\geq 6 months) following COVID-19 diagnosis or hospital discharge.

219 Secondary measures

- 220 ▪ Severity of COVID-19 (mild (including asymptomatic), moderate, severe, critical)

221 *Comparators(controls):*

222 Primary measure

- 223 ▪ People with a confirmed history of COVID-19 without PASC

224 Secondary measures

- 225 ▪ Severity of COVID-19 (mild (including asymptomatic), moderate, severe, critical)

226

227 *Outcomes:*

228 Primary outcome variable

- 229 ➤ Adverse psychiatric outcome
- 230 ▪ Depression
- 231 ▪ Anxiety
- 232 ▪ Substance use disorder
- 233 ▪ Post-traumatic stress disorder
- 234 ▪ Psychosis

235 Secondary outcome variable

- 236 ▪ Self-harm
- 237 ▪ Suicide

238

239 **Information (evidence) sources and search strategies**

240 Information, including titles and abstracts extracted from evidence sources, will be initially
241 screened against the review questions. Information deemed eligible for inclusion will undergo
242 more comprehensive screening. Once an article, study, or review is considered suitable for
243 inclusion, it will be placed in the list of included studies. The steps above will be done for each
244 information source, after which duplicates will be removed. The study selection process will be
245 described in a PRISMA flow diagram and reported in the systematic review.

246 AE will develop the search strategy in consultation with a medical research librarian. The
247 following databases and evidence sources will be searched: PubMed, Ovid MEDLINE,
248 EMBASE, JBI EBP Database, CINAHL Plus, UpToDate, APA PsycInfo, Google Scholar,
249 ProQuest Dissertations & Theses Global, Scopus, Web of Science, the University of Toronto
250 COVID-19 Data & Statistical Sources, Centre for Addiction and Mental Health (CAMH)
251 COVID-19 National Survey Dashboard reports, and COVID-END. Gray literature will also be
252 considered where appropriate. Search strategies will be comprehensive and adapted for each
253 information source. See Appendix 1 for a sample of the PubMed search strategy.

254 The Covidence (Covidence, Melbourne, Australia) or JBI SUMARI software will be used during
255 the systematic review process for screening, appraisal of evidence sources, data extraction,
256 synthesis, and study completion.

257 **Study selection**

258 Information, including titles and abstracts, extracted from information sources will be initially
259 screened by AE and a second reviewer against the research questions. Information deemed
260 eligible for inclusion will undergo more comprehensive screening. Once an article, study, or
261 review is considered suitable for inclusion, it will be placed in the list of included studies. The
262 steps above will be done for each information source, after which duplicates will be removed.
263 Disagreements on inclusion will be resolved through discussion or arbitration. The study
264 selection process will be described in a PRISMA flow diagram and reported in the systematic
265 review.

266 **Data extraction and management**

267 Data will be extracted on primary and secondary outcome measures following the PRISMA
268 guideline for systematic reviews.³⁵ Outcome and effect size measures (e.g., adjusted and
269 unadjusted odds, risk ratios, hazard ratios, standard errors), p-values, and associated 95%
270 confidence intervals. RR for subgroups (e.g., age, sex, duration of PASC, COVID-19 severity)
271 will be extracted if reported. The following data will also be extracted: authorship, publication
272 year, journal name, study design, study location, sample size, baseline characteristics of subjects,
273 demographics (age, sex, ethnicity, or race of subjects,'), study population characteristics (e.g.,
274 general population, prisoners, healthcare workers), the definition of PASC, duration of PASC,
275 comorbidities, other risk factors, duration of follow-up, list of adjusted and unadjusted colliders
276 (e.g., hospitalization, occupation, symptom recognition) and list of adjusted and unadjusted
277 confounders (e.g., age, sex, nature of exposure, type of intervention), propensity methods.³⁴ Two
278 reviewers will conduct data extraction. Discrepancies in data extraction will be resolved through
279 discussion or arbitration.

280 **Risk of bias in individual studies**

281 The JBI critical appraisal checklist will be used to determine the methodological quality and
282 critically appraise the risk of bias for included studies. Assessment will be done at the study and
283 outcome level. Information related to a variable (exposure, outcome, covariate),
284 misclassification, confounding, participant selection, reverse causation, missing data, study
285 power, and generalizability will be appraised. Two reviewers will initially pilot the checklist to
286 enhance consistency, mitigate potential issues with mechanistic scoring, and mitigate
287 performance bias in the overall risk of bias assessment. Studies that do not adequately report on
288 statistical analyses or address confounding, biases (selection, performance, detection, attrition),
289 and other biases will be deemed lower quality studies, i.e., when they consistently have 'no,'
290 'unclear, and 'not applicable' ratings' across relevant items.

291 **Data synthesis**

292 Summary treatment effects estimated as continuous outcomes will be converted to OR, RR, risk
293 difference, and number needed-to-treat (NNT) with a 95% confidence interval (plus the baseline
294 risk) for easier interpretation where possible. A random-effects meta-analysis will be conducted
295 if possible. Statistical heterogeneity across studies will be explored using Higgins I^2 and
296 Cochran's Q statistics. A Cochran's Q test based on a χ^2 statistic with a $p < 0.05$ and greater than
297 the degrees of freedom (df) will indicate heterogeneity. The I^2 statistic will be interpreted as
298 follows: 0-40% = minimal heterogeneity; 30-60% = moderate heterogeneity; 50-90% =
299 substantial heterogeneity; 75-100% = considerable heterogeneity. If there is substantial
300 heterogeneity, subgroup analysis (based on the duration of PASC or COVID-19 severity) will be
301 conducted. Subgroup effect sizes (Cohen's d or Hedges g) and correlations will be assessed and
302 compared with unadjusted values to interpret for meaningful effects. Observed effects will be
303 considered robust if the effect estimates of the primary outcome remain consistent or there are no
304 large differences in the magnitude of effect across subgroups. Subgroup analyses will not be
305 performed if there is minimal or moderate heterogeneity. A formal narrative synthesis will be
306 performed if meta-analysis is not possible. The reasons for not pooling data (e.g., high statistical,
307 methodological, and clinical heterogeneity) will be reported in the review. A methodological

308 quality-based sensitivity analysis presented as a summary table will be used to assess the
309 robustness of the findings. Authors of included studies with missing information will be
310 contacted for clarification. The Grading of Recommendations, Assessment, Development, and
311 Evaluations (GRADE) approach will be used to rate the overall certainty of the evidence
312 obtained from the study.

313 **Patient and public involvement**

314 Input on the review questions and outcomes was informally sought from patients and people who
315 had been previously diagnosed with COVID-19 and PASC.

316 **Ethics and dissemination**

317 Ethical approval is not required for this study. Study findings will be disseminated via preprints,
318 peer-reviewed publications, conference abstracts, posters, plain language summaries,
319 presentations, and infographics.

320 **Ethics statements**

321 **Patient consent for publication**

322 Not applicable.

323 **Contributors:** AE conceived, designed, and drafted the study protocol.

324 **Funding:** This work was supported by the Canadian Institute of Health Research (Grant number:
325 NFRFR-2019-00012). The funding body will not have any role in the systematic review (and
326 meta-analysis) process.

327 **Competing interests:** None declared.

328 **Provenance and peer review:** Not commissioned; externally peer-reviewed.

329

330

331 REFERENCES

- 332 1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR,
333 Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N. Post-acute COVID-19 syndrome. *Nature*
334 *medicine*. 2021 Apr;27(4):601-15.
- 335 2. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Group WC. A clinical case definition
336 of post-COVID-19 condition by a Delphi consensus. *The Lancet Infectious Diseases*. 2021
337 Dec 21.
- 338 3. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19:
339 summary of NICE, SIGN, and RCGP rapid guideline. *bmj*. 2021 Jan 22;372.
- 340 4. Postolache TT, Benros ME, Brenner LA. Targetable biological mechanisms implicated in
341 emergent psychiatric conditions associated with SARS-CoV-2 infection. *JAMA psychiatry*.
342 2021 Apr 1;78(4):353-4.

- 343 5. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and
344 psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using
345 electronic health records. *The Lancet Psychiatry*. 2021 May 1;8(5):416-27.
- 346 6. Santomauro DF, Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, Abbafati C,
347 Adolph C, Amlag JO, Aravkin AY, Bang-Jensen BL. Global prevalence and burden of
348 depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-
349 19 pandemic. *The Lancet*. 2021 Nov 6;398(10312):1700-12.
- 350 7. Fan FC, Zhang SY, Cheng Y. Incidence of psychological illness after coronavirus outbreak: a
351 meta-analysis study. *J Epidemiol Community Health*. 2021 Feb 23.
- 352 8. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-
353 19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the
354 USA. *The Lancet Psychiatry*. 2021 Feb 1;8(2):130-40.
- 355 9. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G,
356 David AS. Psychiatric and neuropsychiatric presentations associated with severe coronavirus
357 infections: a systematic review and meta-analysis with comparison to the COVID-19
358 pandemic. *The Lancet Psychiatry*. 2020 Jul 1;7(7):611-27.
- 359 10. Kaseda ET, Levine AJ. Post-traumatic stress disorder: a differential diagnostic consideration
360 for COVID-19 survivors. *The Clinical Neuropsychologist*. 2020 Nov 16;34(7-8):1498-514.
- 361 11. Moreno-Pérez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jiménez J,
362 Asensio S, Sanchez R, Ruiz-Torregrosa P, Galan I, Scholz A. Post-acute COVID-19
363 syndrome. Incidence and risk factors: A Mediterranean cohort study. *Journal of Infection*.
364 2021 Mar 1;82(3):378-83.
- 365 12. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and
366 management. *bmj*. 2021 Jul 26;374.
- 367 13. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, Horn C,
368 Vanshylla K, Di Cristanziano V, Osebold L, Roventa M. Post-COVID syndrome in non-
369 hospitalised patients with COVID-19: a longitudinal prospective cohort study. *The Lancet*
370 *Regional Health-Europe*. 2021 Jul 1;6:100122.
- 371 14. Mendez R, Balanzá-Martínez V, Luperdi SC, Estrada I, Latorre A, González-Jiménez P,
372 Feced L, Bouzas L, Yopez K, Ferrando A, Hervas D. Short-term neuropsychiatric outcomes
373 and quality of life in COVID-19 survivors. *Journal of internal medicine*. 2021 Feb 3.
- 374 15. Vannorsdall T, Oh ES. Post-acute cognitive and mental health outcomes amongst COVID-19
375 survivors: early findings and a call for further investigation. *Journal of Internal Medicine*.
376 2021 Sep 1.
- 377 16. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, Lekoubou A, Oh JS, Ericson
378 JE, Ssentongo P, Chinchilli VM. Short-term and long-term rates of post-acute sequelae of
379 SARS-CoV-2 infection: a systematic review. *JAMA network open*. 2021 Oct
380 1;4(10):e2128568-.
- 381 17. Forte G, Favieri F, Tambelli R, Casagrande M. COVID-19 pandemic in the Italian
382 population: validation of a post-traumatic stress disorder questionnaire and prevalence of
383 PTSD symptomatology. *International Journal of Environmental Research and Public Health*.
384 2020 Jan;17(11):4151.
- 385 18. Khubchandani J, Price JH, Sharma S, Webb FJ. COVID-19 Infection Survivors and the Risk
386 of Depression and Anxiety Symptoms: A Nationwide Study of Adults in the United States.
387 *European Journal of Internal Medicine*. 2022 Jan 12.

- 388 19. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-
389 19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the
390 USA. *The Lancet Psychiatry*. 2021 Feb 1;8(2):130-40.
- 391 20. Varatharaj A, Thomas N, Ellul MA, Davies NW, Pollak TA, Tenorio EL, Sultan M, Easton
392 A, Breen G, Zandi M, Coles JP. Neurological and neuropsychiatric complications of
393 COVID-19 in 153 patients: a UK-wide surveillance study. *The Lancet Psychiatry*. 2020 Oct
394 1;7(10):875-82.
- 395 21. Pinna P, Grewal P, Hall JP, Tavarez T, Dafer RM, Garg R, Osteraas ND, Pellack DR,
396 Asthana A, Fegan K, Patel V. Neurological manifestations and COVID-19: experiences from
397 a tertiary care center at the frontline. *Journal of the Neurological Sciences*. 2020 Aug
398 15;415:116969.
- 399 22. Orrù G, Rebecca C, Gemignani A, Conversano C. Psychological intervention measures
400 during the COVID-19 pandemic.
- 401 23. Biagianti B, Zito S, Fornoni C, Ginex V, Bellani M, Bressi C, Brambilla P. Developing a
402 Brief Tele-Psychotherapy Model for COVID-19 Patients and Their Family Members.
- 403 24. Damiano RF, Di Santi T, Beach S, Pan PM, Lucchetti AL, Smith FA, Forlenza OV,
404 Fricchione GL, Miguel EC, Lucchetti G. Mental health interventions following COVID-19
405 and other coronavirus infections: a systematic review of current recommendations and meta-
406 analysis of randomized controlled trials. *Brazilian Journal of Psychiatry*. 2021 Apr 12.
- 407 25. Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on
408 anxiety and sleep quality in patients with COVID-19. *Complementary therapies in clinical
409 practice*. 2020 May 1;39:101132.
- 410 26. Sotoudeh HG, Alavi SS, Akbari Z, Jannatifard F, Artounian V. The effect of brief crisis
411 intervention package on improving quality of life and mental health in patients with COVID-
412 19. *Iranian journal of psychiatry*. 2020 Jul;15(3):205.
- 413 27. Islam MN, Islam AN. A systematic review of the digital interventions for fighting COVID-
414 19: the Bangladesh perspective. *Ieee Access*. 2020 Jun 15;8:114078-87.
- 415 28. Rauschenberg C, Schick A, Hirjak D, Seidler A, Paetzold I, Apfelbacher C, Riedel-Heller
416 SG, Reininghaus U. Evidence synthesis of digital interventions to mitigate the negative
417 impact of the COVID-19 pandemic on public mental health: rapid meta-review. *Journal of
418 medical Internet research*. 2021 Mar 10;23(3):e23365.
- 419 29. Khilnani A, Schulz J, Robinson L. The COVID-19 pandemic: new concerns and connections
420 between eHealth and digital inequalities. *Journal of Information, Communication and Ethics
421 in Society*. 2020 Jun 23.
- 422 30. Gega L, Aboujaoude E. How Digital Technology Mediated the Effects of the COVID-19
423 Pandemic on Mental Health: The Good, the Bad, and the Indifferent. *Frontiers in Digital
424 Health*. 2021;3.
- 425 31. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome
426 measures after COVID-19: a prospective cohort study. *European Respiratory Journal*. 2020
427 Nov 1;56(5).
- 428 32. Schou TM, Joca S, Wegener G, Bay-Richter C. Psychiatric and neuropsychiatric sequelae of
429 COVID-19—A systematic review. *Brain, Behavior, and Immunity*. 2021 Oct 1;97:328-48.
- 430 33. Schwab K, Schwitzer E, Qadir N. Post-Acute Sequelae of COVID-19 Critical Illness. *Critical
431 Care Clinics*. 2022 Jan 10.

432 34. Moher D, Shamseer L, Clarke M, Gherzi D, Liberati A, Petticrew M, Shekelle P, Stewart
433 LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-
434 P) 2015 statement. *Systematic reviews*. 2015 Dec;4(1):1-9.

435 35. Caliendo AM, Hanson KE. RELATED PATHWAYS. COVID-19 diagnosis. UpToDate.
436 2022 Jan 21.

437 36. Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, Sharp GC, Sterne J,
438 Palmer TM, Smith GD, Tilling K. Collider bias undermines our understanding of COVID-19
439 disease risk and severity. *Nature communications*. 2020 Nov 12;11(1):1-2.

440 37. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L,
441 Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated
442 guideline for reporting systematic reviews. *Bmj*. 2021 Mar 29;372.

443

444

445

446

447

448

449

450

451

452

453

454